. At our institution, patients undergoing these operations are subject to a same-day discharge algorithm that incorporates post-anesthesia-care-unit (PACU) rapid PTH as the major discharge criterion. Patients with PTH Ͼ30 (pg/ml) are eligible for same-day discharge from PACU without supplementation, PTH Ͼ20 are eligible for discharge but receive calcium supplementation, and PTH Ͻ20 are observed overnight (23 hours) with calcium and vitamin D supplementation. RESULTS: 180 patients (mean age 48.9, 83.3% female) underwent total (77.2%) or completion (22.7%) thyroidectomy with or without node dissection (42.2% minimally invasive video assisted). Seventy-six percent (137/180) of patients had a PTH Ͼ20, meeting PTH discharge criterion. Sixty-nine percent of those eligible (95/137) were discharged same-day (53.1% of total). Of the 95 patients undergoing outpatient surgery, none were admitted, seen, or called with symptoms of hypocalcemia. Mean PACU PTH was not significantly different from pre-operative PTH (43.4 vs. 38.7, pϭ0.10). Mean adjusted total calcium in PACU was 8.7 ϩ/-0.5 (mg/dl). Of the 85 patients observed overnight, 11.1% were hypocalcemic on post-op day (POD) 1. Of the 42 patients observed despite PTH Ͼ20, 7.1% had asymptomatic POD1 hypocalcemia. All 180 patients were eucalcemic (Ca Ͼ8) at POD7 and POD30 office visits. No patients were hypoparathyroid at POD30. CONCLUSION: A PTH-based discharge algorithm can safely facilitate outpatient completion or total thyroidectomy, with minimal risk of clinically significant outpatient hypocalcemia.
Patterns of Lymph Node Metastasis in Advanced
Auricular SCCA Joe Kutz, MD (presenter); Larry Myers, MD OBJECTIVE: Be able to determine the incidence and pattern of regional metastasis in patients presenting with advanced squamous cell carcinoma involving the auricle. METHOD: Study population identified by CPT coding for partial/total auriculectomy, parotidectomy, and temporal bone resection through the University of Texas Southwestern and associated hospitals from 1996 through 2008. Patients needed to be above 18 years of age and have stage III/IV disease. Approximately 840 charts reviewed. At this point in time, 46 patients met inclusion criteria. RESULTS: Of the 46 patients, 82.6% (nϭ38) were stage 4, 17.4% (nϭ8) stage 3. 33 (71.7%) patients had a prior history of non-auricular non-melanotic skin carcinoma, 8 (17.4%) of which had prior radiation therapy. Overall, 35 (77.8%) patients showed either direct extension to the parotid(nϭ19), regional metastasis to the cervical drainage basin(nϭ18), or metastasis to the periparotid lymph nodes(nϭ7). Level of cervical metastasis was found to be 6.7% level 1 (nϭ1), 80% level 2 (nϭ12), 46.6% level 3 (nϭ7), 13.3% level 4 (nϭ2), and 40% (nϭ6) level 5. Of note, the six patients with a level 5 metastasis were of preauricular (nϭ3), auricular (nϭ2), and postauricular (nϭ1) primary subsite. Of the study population, only 2 patients (4.3%) were found to have cervical metastasis without preoperative evidence of regional metastasis by clinical exam or radiographic evidence. 81.1% (30/37) of patients with documentation were found to have evidence of perineural invasion. There was a high recurrence rate of 43.5% (nϭ20) during followup with an average of 12.5 mos (range 1.5 84.0 mos). Thirty% (nϭ6) of recurrences had positive margins at initial resection. CONCLUSION: Patients with advanced stage auricular cutaneous squamous cell carcinoma can be expected to have aggressive disease with high rates of regional metastasis and recurrence. When planning neck dissections for these patients, level 5 should be included in the resection. Patients demonstrating locally advanced disease without evidence of metastasis to the parotid or cervical drainage basin can be considered for close monitoring of the neck and forego the morbidity of neck dissection.
Planned Neck Dissection after CCR for HNSCC: Is It Necessary
Amy Whigham, MD (presenter); Michelle Pham, BS; Wendell Yarbrough, MD; Jonathan Law, MD OBJECTIVE: Patients with head and neck squamous cell carcinoma (HNSCC) with advanced cervical nodal metastases (N2 or N3) have traditionally been treated with a planned neck dissection following treatment with concurrent chemotherapy and radiation (CCR). Controversy exists regarding the need for these planned neck dissections given the good response of cervical metastases to CCR. The purpose of this study was to analyze survival of patients that presented with advanced cervical nodal metastases to determine if planned neck dissection affected regional or distant metastatic rates or survival. METHOD: A retrospective analysis reviewed all patients that presented to our multidisciplinary head and neck oncology team between 1997 and 2006. Enrollment criteria included HNSCC patients with N2 or N3 cervical nodal disease with first line treatment by CCR. Tumor stage, recurrence, and survival data were analyzed for patients that received planned neck dissections versus no neck dissection. Secondary analyses based on primary tumor site (oropharyngeal vs. laryngeal) and year of treatment were performed to determine if there was a change in planned neck dissections over time and if this correlated with outcome within our institution. RESULTS: A total of 2593 charts of patients treated between 1997 and 2006 were reviewed, yielding 165 patients who met inclusion criteria. After CCR, 52 patients had neck dissections and 113 patients did not receive a neck dissection. There were no statistically significant differences in overall survival (OS) or disease free survival (DFS) based on neck dissection status. However, from 1997-2002, 30/80 (38%) of N2 or N3 patients received a neck dissection after CCR whereas only 22/85 (25%) of similar patients were treated with neck dissections P69 Oral Presentations
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